Boezaart et al. also reported two cases of patients with severe COVID-19 receiving transcutaneous aVNS in addition to SOC, which led to a rapid decrease of IL-6 (Boezaart and Botha, 2021). This evidence concerns the gene IL6 and COVID-19.